Key Product Details
Product Summary for Human TRAIL R2/TNFRSF10B PE‑conjugated Antibody
Accession # O14763
Scientific Data Images for Human TRAIL R2/TNFRSF10B PE‑conjugated Antibody
MDA‑MB‑231 Human Cell Line by Flow Cytometry.MDA-MB-231 human breast cancer cell line was stained with Mouse Anti-Human TRAIL R2/TNFRSF10B PE-conjugated Monoclonal Antibody (Catalog # FAB6311P, filled histogram) or isotype control antibody (Catalog # IC0041P, open histogram). View our protocol for Staining Membrane-associated Proteins.
Applications for Human TRAIL R2/TNFRSF10B PE‑conjugated Antibody
Sample: MDA‑MB‑231 human breast cancer cell line
Read 1 review rated 4 using FAB6311P in the following applications:
Read 27 publications using FAB6311P in the following applications:
Formulation, Preparation and Storage
Stability & Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: TRAIL R2/TNFRSF10B
Human TRAIL R2, also known as DR5 and TRICK 2, is a type 1, TNF R family, transmembrane protein which is a receptor for TRAIL (APO2 Ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.
Product Specific Notices for Human TRAIL R2/TNFRSF10B PE‑conjugated Antibody
For research use only